Variable | Categorization | GLI1 nuclear immunoreactivityb 0–6 vs 7–12 | |||
---|---|---|---|---|---|
n analyzable | low | high | P c | ||
Clinicopathological data: | |||||
Tumour stagea | |||||
pT1 | 57 | 34 | 23 | <0.001 | |
pT2 | 87 | 19 | 68 | ||
pT3 | 12 | 3 | 9 | ||
pT4 | 28 | 8 | 20 | ||
Lymph node status | |||||
pN0 | 78 | 36 | 42 | 0.027 | |
pN1-3 | 100 | 30 | 70 | ||
Histologic grade | |||||
G1 | 21 | 10 | 11 | 0.191 | |
G2 | 81 | 29 | 52 | ||
G3 | 82 | 25 | 57 | ||
Multifocality | |||||
unifocal tumour | 161 | 57 | 104 | 0.844 | |
multifocal tumour | 24 | 8 | 16 | ||
Histologic type | |||||
ductal | 152 | 57 | 95 | 0.312 | |
lobular | 14 | 3 | 11 | ||
other | 17 | 5 | 2 | ||
Immunohistochemistry (IHC): | |||||
Oestrogen receptor status | |||||
negative | 53 | 19 | 34 | 0.484 | |
positive | 96 | 29 | 67 | ||
Progesterone receptor status | |||||
negative | 109 | 33 | 76 | 0.266 | |
positive | 51 | 20 | 31 | ||
HER2 status | |||||
weak (0–2+) | 132 | 45 | 87 | 0.847 | |
strong (3+) | 31 | 10 | 21 |